12:00 AM
 | 
Feb 17, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/14 cls
Depomed Inc. (NASDAQ:DEPO) Roth Capital Partners Scott Henry Downgrade Neutral (from buy) 1% $12.30
Henry downgraded on the belief that the share price has caught up to fundamentals after doubling in the past 12 months. He raised his target to $12.50 from $12 after increasing his sales forecasts for migraine drug Cambia diclofenac oral solution to $27M in 2014 and $37M in 2015. Last December, Depomed gained U.S. rights to Cambia from Nautilus Neurosciences Inc.
Genetic Technologies Ltd. (ASX:GTG; NASDAQ:GENE) Ladenburg Thalmann Kevin DeGeeter Upgrade Buy (from neutral) 31% $1.90
DeGeeter also introduced a $2.50 target ahead of the...

Read the full 776 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >